

Immunovaccine's Preclinical DPX-NEO Program Demonstrates Positive Anti-Cancer Activity

[Spotlight Companies Follow](#) | Monday, 07 November 2016 14:35 (EST)

Immunovaccine (IM.V), a biotechnology company, is dedicated to advancing cancer therapies and infectious disease vaccines. The Halifax-based company's DepoVax™ platform has been credited as the foundation of all its vaccine development efforts.

According to the company's official website, DepoVax™ is a patented vaccine delivery formulation that provides controlled and prolonged exposure of antigens plus adjuvant to the immune system. The result is a strong, specific and sustained immune response with the capability for single-dose effectiveness. Currently, the company boasts an impressive product pipeline that includes candidates being developed to address the unmet needs within cancer therapies and the treatment of infectious diseases.

As with most great works, Immunovaccine has collaborated with some of the most recognizable names in medical research. The company's partners, among others, include:

- Pfizer
- NIH
- MERCK

In recent news, Immunovaccine announced a key development regarding its preclinical studies. In collaboration with UConn Health, the Immunovaccine's preclinical DPX-NEO program, which used neoepitope formulated with the DepoVax™ platform in mouse tumor models, have demonstrated positive anti-cancer activity.

"This study provides evidence that the DepoVax™ platform can serve as an optimal enabling formulation technology to deliver strong and sustained immune responses against tumors with neoepitopes, an approach that we believe is a promising option for advancing personalized cancer medicines," said Frederic Ors, CEO of Immunovaccine. "With our novel DepoVax™ platform and cost-effective, scalable manufacturing capabilities, we believe Immunovaccine can play an important role advancing clinical progress for neoepitope therapies as this exciting field evolves."

The biotechnology sector continues to be a fascinating and increasingly promising sector with new groundbreaking treatment innovations on the horizon. As reported by Healio, Immunovaccine, as of March of this year, was one of six companies or government agencies working on about 17 RSV vaccine candidates, A vaccine for respiratory syncytial virus, in various stages of clinical trials.

"Our primary indication is in the elderly, who have gotten RSV multiple times, so they have immune responses to F and G and they're not protected," Marianne Stanford, PhD, vice president of research at Immunovaccine. "Our hypothesis is, let's mount an immune response against something that they don't typically have an immune response to, and then sort of circumvent infection that way. That makes it very different from everything else that's out there. What we're trying to do is target immune response not against the virus particle, but against the infected cell."

Furthermore, earlier this month, KIMT reported that a new vaccine for Glioblastoma, the most common and most severe form of brain cancer, showed promising results for researchers in Buffalo, New York.

Patient Margie Kruse was diagnosed with the cancer last year. Following a Phase II clinical trial for the vaccine currently being conducted at Roswell Park Cancer Institute in Buffalo, her tumor was a no-show in her most recent MRI. "This vaccine has been absolutely a godsend," Kruse told KIMT.

Thanks to its recent positive preclinical results and its continued efforts to provide rays of hope to patients diagnosed with devastating diseases, the investment community looks forward to future developments from Immunovaccine and the biotech sector as a whole.

To learn more about Immunovaccine, visit www.imvaccine.com.

In the interest of full disclosure, we call the reader's attention to the fact that Equities.com, Inc. is compensated by the companies profiled in the Spotlight Companies section. The purpose of these profiles is to provide awareness of these companies to investors in the micro, small-cap and growth equity community and should not in any way be considered as a recommendation to buy, sell or hold these securities. Equities.com is not a registered broker dealer, investment advisor, financial analyst, investment banker or other investment professional. We are a publisher of original and third party news and information. All profiles are based on information that is available to the public. The information contained herein should not be considered to be complete and is not guaranteed by Equities.com to be free from misstatement or errors. The views expressed are our own and not intended to be the basis for any investment decision. Readers are reminded to do their own due diligence when researching any companies mentioned on this website. Always bear in mind that investing in early-stage companies is risky and you are encouraged to only invest an amount that you can afford to lose completely without any change in your lifestyle. Equities has been compensated with a combination of cash, common stock and/or warrants for market awareness services provided to our client.

DISCLOSURE: *The views and opinions expressed in this article are those of the authors, and do not represent the views of [equities.com](http://www.equities.com). Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: <http://www.equities.com/disclaimer>*